$97.49
1.71% yesterday
NYSE, May 20, 10:10 pm CET
ISIN
US3773221029
Symbol
GKOS

Glaukos Corp Stock price

$97.49
+9.19 10.41% 1M
-43.95 31.07% 6M
-52.45 34.98% YTD
-11.78 10.78% 1Y
+58.15 147.81% 3Y
+59.94 159.63% 5Y
+66.27 212.27% 10Y
NYSE, Closing price Tue, May 20 2025
+1.64 1.71%
ISIN
US3773221029
Symbol
GKOS
Sector

Key metrics

Market capitalization $5.57b
Enterprise Value $5.38b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.29
P/S ratio (TTM) P/S ratio 13.77
P/B ratio (TTM) P/B ratio 7.24
Revenue growth (TTM) Revenue growth 23.92%
Revenue (TTM) Revenue $404.52m
EBIT (operating result TTM) EBIT $-101.48m
Free Cash Flow (TTM) Free Cash Flow $-53.24m
Cash position $298.70m
EPS (TTM) EPS $-2.31
P/E forward negative
P/S forward 11.59
EV/Sales forward 11.18
Short interest 8.15%
Show more

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Glaukos Corp forecast:

13x Buy
81%
2x Hold
13%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Glaukos Corp forecast:

Buy
81%
Hold
13%
Sell
6%

Financial data from Glaukos Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
405 405
24% 24%
100%
- Direct Costs 98 98
36% 36%
24%
306 306
21% 21%
76%
- Selling and Administrative Expenses 231 231
19% 19%
57%
- Research and Development Expense 138 138
3% 3%
34%
-62 -62
15% 15%
-15%
- Depreciation and Amortization 39 39
2% 2%
10%
EBIT (Operating Income) EBIT -101 -101
9% 9%
-25%
Net Profit -124 -124
12% 12%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Neutral
Business Wire
8 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May...
Neutral
Seeking Alpha
20 days ago
Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Larry Biegelsen - Wells Fargo Allen Gong - J.P. Morgan Davi...
Neutral
Business Wire
20 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Thomas Burns
Employees 995
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today